Trading high volume, page-151

The good old Madam !
As noted - in my opinion.

Point is - you say the Teva R/ship is dubious...fair enough as well because like me its your opinion.

However I say Teva R/ship is solid and thick (based on CEO comments and analyst notes).
And from my point of view, I also say it would make logical sense that the r/ship could be further enhanced with the following announcements:

19/3/2015:
MESOBLAST SELECTED FOR FAST TRACK ACCESS TO POTENTIAL INVESTMENT INCENTIVES IN JAPAN ; and

27/3/2015:
MESOBLAST KEY PATENT ALLOWED IN JAPAN FOR THE TREATMENT OF HEART DISEASES, STROKE, AND OTHER VASCULAR CONDITIONS

Teva have a good presence in Japan and with the support of JETRO - why wouldn't any commercially driven Pharma look to take advantage of the "new" Regenerative Medicine laws in Japan – particularly when there are potentiall significant incentives.

Madam – do you see any negatives in the above 2 announcements ?


DYOR. Above just in my opinion.
GLTAH - 2015